Harrington Robert Arthur 4

What Happened

Robert A. Harrington, a director of Cytokinetics, received a grant of 151 shares of common stock on 2026-07-15 (reported on Form 4). The shares were granted at a reported value/price of $82.62 per share, for a total value of approximately $12,476. This was an award/acquisition (transaction code A) issued under the company's Equity in Lieu of Cash Retainer Program; the shares were fully vested at the time of grant.

Key Details

• Transaction date: 2026-07-15; Form 4 filed 2026-07-16 (timely filing).
• Price/value: $82.62 per share; total ≈ $12,476.
• Shares granted: 151 common shares (fully vested at grant) — transaction code A (award/grant).
• Footnote: Shares granted pursuant to Cytokinetics Equity in lieu of Cash Retainer Program; fully vested at grant (F1).
• Shares owned after transaction: not specified in the provided summary—see the full Form 4 for total holdings.
• Accession #: 0001061983-26-000079.

Context

This was a routine director compensation grant (equity awarded instead of cash retainer) and does not represent an open-market purchase or sale. Because the shares are fully vested, Harrington has immediate ownership and can hold or sell them like any other shares. Equity awards to directors are common and generally reflect compensation, not a direct buy/sell signal about the company's short-term outlook.